Serina Therapeutics presents at Injectables Summit with Enable on SER-252 for Parkinson's

Serina Therapeutics, Inc.

Serina's CDO Randall Moreadith presents at 14th Annual Injectables Summit in Boston on October 2, 2024.
Joint presentation with Enable Injections' CCO Matthew Huddleston focuses on SER-252 for advanced Parkinson's disease.
Partnership combines Serina's SER-252 with Enable's enFuse wearable drug delivery platform.
No financial results, guidance, or other material corporate updates were provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.